Legend Biotech (LEGN) Misses Q2 EPS by 21c

Legend Biotech (NASDAQ: LEGN) reported Q2 EPS of ($0.57), $0.21 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $73.33 million versus the consensus estimate of $54.56 million.

For earnings history and earnings-related data on Legend Biotech (LEGN) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Ennis (EBF) Reports In-Line Q1 EPS
• Deutsche Bank Starts DexCom (DXCM) at Buy